A group of WHO scientists advised to stop treatment with blood plasma of COVID-19 patients 
A group of international experts from the World Health Organization (WHO) advised to stop treatment with coronavirus blood plasma of COVID-19 patients. This is stated in a press release from the organization, which was received by Lenta.ru.
According to WHO scientists, current data show that this method of treatment does not reduce the risk of death from coronavirus or the likelihood of being on mechanical ventilation, but plasma treatment is costly and time consuming.
Thus, WHO opposes the use of plasma from recovered patients for patients with mild, moderate and severe disease. Recommendations are based on data from 16 studies involving 16,236 patients with mild, severe and critical COVID-19 infection.
These recommendations are part of the guidance developed by the World Health Organization with the methodological support of the MAGIC Evidence Ecosystem Foundation to provide reliable provide advice on how to treat COVID-19 and help doctors make better decisions about treating patients.
The recommendation for patients with mild disease reflects the panel's view that drug treatment for patients with a low risk of death or severe disease is not warranted.
Experts also noted several practical problems, such as the need to identify and test potential donors , as well as the collection, storage and administration of donor plasma, which, they say, further limits its feasibility and applicability. In addition, after carefully reviewing all the information, the team concluded that almost all well-informed patients about the coronavirus would prefer not to receive plasma as a treatment.
In September, the WHO Guidelines Development Group recommended the use of the cocktail from antibodies “REGEN-COV for two groups of patients. The first group consists of patients with non-severe COVID-19 with the highest risk of hospitalization. The second is made up of severely or critically ill coronavirus infection who are seronegative – unable to develop antibodies against COVID-19.